Alzheimer’s is diagnosed through a clinical evaluation: a history, cognitive testing, imaging and, where needed, biomarker tests. Since May 2025 the FDA has cleared several blood tests, including pTau217 tests, that measure Alzheimer’s-related proteins, but they are cleared only for people who already have memory or thinking symptoms, and a clinician must interpret them alongside everything else. If changes in memory are getting in the way of daily life, the practical next step is a medical evaluation, not a home test.
Early signs of Alzheimer’s vs normal aging
Everyone forgets things. The Alzheimer’s Association’s ten warning signs separate a pattern that interferes with daily life from the occasional slip that comes with age:
| Area | Typical age-related change | Worth a medical visit |
|---|---|---|
| Memory | Forgetting a name or appointment, remembering it later | Memory loss that disrupts daily life |
| Planning and problem-solving | An occasional error with bills or finances | Trouble following a plan or working with numbers |
| Familiar tasks | Needing help with microwave settings or recording a show | Difficulty completing tasks done for years |
| Time and place | Confusion about the day of the week, worked out later | Losing track of dates, seasons or where you are |
| Words | Sometimes searching for the right word | New problems speaking or writing |
| Misplacing things | Losing items, then retracing steps to find them | Losing the ability to retrace steps |
| Judgment and mood | An occasional poor decision; irritation when a routine is disrupted | Poor judgment, withdrawal from social life, personality change |
Sudden confusion is a different problem. It can point to delirium, a different condition that needs prompt medical attention; see our guide to delirium vs dementia.
How is Alzheimer’s diagnosed?
There is no single test. Per the Alzheimer’s Association, the usual path looks like this:
- Primary care visit and cognitive screen. Short tools such as the AD8, SLUMS or MMSE, plus a history from the patient and someone who knows them well. A neuropsychologist may give longer testing.
- Rule out other causes. Structural MRI or CT mainly checks for tumors, strokes, head trauma or fluid buildup.
- Specialist evaluation. A neurologist, geriatrician or memory clinic. In New York State, the Department of Health designates Centers of Excellence for Alzheimer’s Disease; the New York City region ones are NYU Langone, Columbia University Irving Medical Center and SUNY Downstate.
- Biomarker confirmation, when it will change decisions. Amyloid PET, a spinal-fluid (CSF) test through lumbar puncture, or one of the blood tests below.
Home “memory screening” kits are not recommended: the Association says they have not been scientifically proven accurate and can give false positives.
Which Alzheimer’s blood tests has the FDA cleared?
As of 8 October 2026, four blood tests are FDA-cleared, according to the Alzheimer’s Association. Details differ by test:
| Test | Announced | Cleared for | What to know |
|---|---|---|---|
| Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio) | 16 May 2025 | Age 55+ with signs of cognitive decline, in specialized care | First one cleared. In the FDA’s study of 499 samples, 91.7% of positives and 97.3% of negatives matched PET or CSF results |
| Elecsys pTau181 (Roche) | 13 Oct 2025 | Age 55+ with cognitive symptoms, in primary care | Meant to help rule out amyloid pathology; Roche reports a 97.9% negative predictive value in a primary-care-like group of 312 people |
| Elecsys pTau217 (Roche) | 24 Aug 2026 | Age 55+ with cognitive symptoms, in primary and specialty care | Results fall in positive, intermediate or negative categories |
| PrecivityAD2 (C2N Diagnostics) | 20 Aug 2026 | Age 40+ with cognitive symptoms | Company reports 97.6% PPV and 93.1% NPV in 1,142 people; 17.3% got a “likely positive” result with only 77.3% PPV. Cleared version expected later this year |
The first row comes from the FDA’s own announcement; the other three rest on manufacturer releases and the Alzheimer’s Association, because we could not retrieve the FDA pages for them.
The limits matter more than the headlines
- Not screening. The FDA says the Lumipulse test is “not intended as a screening or stand-alone diagnostic test.” The Alzheimer’s Association states these tests are not screening tests for symptom-free people.
- They detect amyloid, not dementia. Roche states that safety and effectiveness are not established for predicting who will develop dementia, or for monitoring treatment.
- Errors both ways. The FDA names false positives (wrong diagnosis, unneeded treatment) and false negatives (delayed treatment) as the main risks. Intermediate results need further testing.
Why bother? Two anti-amyloid drugs, lecanemab (Leqembi) and donanemab (Kisunla), have FDA approval for early Alzheimer’s (mild cognitive impairment or mild dementia) when elevated amyloid is confirmed. Per the Alzheimer’s Association, they can cause brain swelling or bleeding (ARIA), and the FDA encourages ApoE ε4 testing before starting. Earlier answers also give a family time to plan, which we cover below.
Why are more women affected?
According to the Alzheimer’s Association’s 2026 Facts and Figures, almost two-thirds of Americans with Alzheimer’s are women. Its page on women says the prevailing view has been that women live longer on average, and age is the greatest risk factor. The same page adds that researchers are asking whether women’s risk could be higher at any given age because of biological, genetic or life-experience differences.
So longevity is the established part; other causes are still being studied, and claims that hormones or one gene explain it should be read as hypotheses. The Association also notes that more than 60% of Alzheimer’s and dementia caregivers are women, which is why this affects whole families, not only patients.
Which risk factors can you change?
The 2024 Lancet Commission on dementia prevention (Livingston et al.) names 14 modifiable risk factors and estimates that addressing all of them could prevent or delay about 45% of dementia. That is a population estimate that assumes the links are causal, not a promise for any one person. The Commission also notes that risk is modifiable regardless of APOE status.
| Risk factor | What the Commission recommends |
|---|---|
| Less education | Good-quality education for all; stay cognitively active in midlife |
| Hearing loss | Make hearing aids accessible; reduce harmful noise exposure |
| Vision loss (new in 2024) | Accessible screening and treatment for vision impairment |
| High LDL cholesterol (new in 2024) | Detect and treat from midlife |
| High blood pressure | Aim to keep systolic pressure at or below 130 mm Hg from age 40 |
| Obesity and diabetes | Maintain a healthy weight; treating obesity early also helps prevent diabetes |
| Physical inactivity | Encourage exercise |
| Smoking, excessive alcohol | Smoking-cessation support; reduce heavy drinking |
| Depression | Treat it effectively |
| Traumatic brain injury | Helmets and head protection in contact sports and on bikes |
| Social isolation | Support participation in activities and living with others |
| Air pollution | Reduce exposure |
First signs of Alzheimer’s and what to do: advice from our nurse director
Anna Klyauzova, RN, MSN, MPA, Director of Patient Services at ProLife Home Care, on what she sees in practice:
Families usually come to us once memory problems start getting in the way: Mom leaves the stove on, mixes up her pills or gets lost on a street she has known for years. Please don’t wait for something serious to happen. See a doctor at the first changes you can’t explain.
In the first weeks after a diagnosis, don’t try to rebuild your whole life in a day. Set up a simple daily routine, make the home safer and go through the treatment plan with the doctor. Ask early who will support the main caregiver. Our Alzheimer’s and dementia care is there for the person and for the family around them.
What families rarely hear: don’t argue and don’t keep correcting. If your mother asks the same question for the fifth time, she isn’t doing it on purpose. A calm voice, familiar surroundings and a predictable routine usually help more than long explanations.
What to do after a concerning result
- Book a visit and bring a witness. Take someone who sees the person daily, a written list of changes with dates, and every medication.
- Ask for the Medicare cognitive assessment. Medicare Part B covers a separate visit to fully review cognitive function and produce a care plan. After the Part B deductible you pay 20% of the Medicare-approved amount.
- Get a specialist opinion if the picture is unclear, ideally a memory clinic or one of the state Centers of Excellence listed above.
- Call for support before a crisis. See the table below.
- Put legal papers in place while the person can still sign them. A health care proxy and power of attorney are far easier now; see our page on POA and guardianship.
| Resource | What it offers | Contact |
|---|---|---|
| Alzheimer’s Association 24/7 Helpline | Confidential, free; interpreters in 200+ languages; free care consultations. Staff do not give diagnoses or medical advice | 1-800-272-3900 (dial 711 for relay) |
| Alzheimer’s Association, New York City Chapter | Education programs, caregiver and early-stage support groups, programs in Spanish and Mandarin | alz.org/nyc, or the Helpline |
| CaringKind (NYC) | Helpline staffed by navigators; support groups, education, Cognitive Stimulation Therapy | (646) 744-2900 |
| NYS Alzheimer’s Disease Caregiver Support Initiative | State program since 2015, covering all 62 counties: Centers of Excellence, regional caregiver support organizations, and AlzCAP | health.ny.gov/alz |
As the care needs grow, our dementia care at home page explains how needs change by stage, and our Alzheimer’s care page covers what we provide. If the main caregiver is wearing down, respite care and adult day care are the usual first steps. We are a licensed home care agency in Brooklyn and Queens, licence #2572L001: call (718) 232-2777 or use our contact page. We do not diagnose; we help families work out the care side.
General information, not medical advice. Diagnosis and treatment decisions belong with the person’s own clinician. FDA clearances and program details change; everything above was checked on 8 October 2026 against fda.gov, alz.org, medicare.gov, health.ny.gov, Roche and the Lancet Commission report.
Frequently asked questions
Is there a blood test for Alzheimer’s disease?
Yes. As of October 2026 the FDA has cleared four blood tests that measure Alzheimer’s-related proteins, including pTau217 tests, for adults with cognitive symptoms. They support, but do not replace, a full clinical evaluation.
Can I get a pTau217 blood test if I have no symptoms?
Not as an FDA-cleared use. The clearances cover people with signs or symptoms of cognitive decline, and the Alzheimer’s Association says these are not screening tests for symptom-free people. A positive result in someone without symptoms is hard to interpret.
Why do more women than men have Alzheimer’s?
Almost two-thirds of Americans with Alzheimer’s are women. The prevailing explanation is that women live longer and age is the biggest risk factor, though researchers are studying whether biology, genetics or life experience also raise risk at a given age.
Can Alzheimer’s be prevented?
Not with certainty. The 2024 Lancet Commission estimates that about 45% of dementia could potentially be prevented or delayed by addressing 14 modifiable risk factors, such as untreated hearing loss, high blood pressure and high LDL cholesterol. That is a population-level estimate.
Does Medicare cover a memory evaluation?
Medicare Part B covers a separate visit to review cognitive function and create a care plan. After the Part B deductible you pay 20% of the Medicare-approved amount, though your own cost depends on other coverage and the provider.
Who can I call in New York City about memory loss?
The Alzheimer’s Association Helpline at 1-800-272-3900 is open 24/7 and offers free care consultations. In New York City, CaringKind’s helpline is (646) 744-2900.
How do I tell normal forgetfulness from early Alzheimer’s?
Normal aging usually means forgetting a name or appointment and remembering it later. Memory loss that disrupts daily life, such as repeated questions, missed bills or getting lost on familiar routes, is a reason to see a doctor.
